Umans J.G.,MedStar Research Institute
Clinical journal of the American Society of Nephrology : CJASN | Year: 2012
Preeclampsia, a common and potentially devastating multisystem disorder unique to human pregnancy, represents a novel form of secondary hypertension with complex renal and systemic effects. Recent translational and clinical research reveals key pathophysiologic contributions due to dysregulation of angiogenic factors and of angiotensin signaling. Despite these insights, there are still difficulties in the clinical definition of preeclampsia and in the diagnosis of women with this disorder. Although recent research suggests the potential for new preventive and treatment strategies, most have not yet been shown ready for clinical use.
Brewer Jr. H.B.,MedStar Research Institute
Journal of Clinical Endocrinology and Metabolism | Year: 2011
Context: Statin treatment of cardiovascular patients reduces clinical events by 25 to 45%. Highdensity lipoprotein (HDL) has been proposed as a therapeutic target to further reduce this residual cardiovascular risk. Evidence Acquisition: PubMed from 1940 to the present was searched for all relevant citations related to the structure, function, and role of HDL in atherosclerosis. Evidence Synthesis: Epidemiological data, animal models with increased plasma HDL levels, as well as initial clinical and cardiovascular imaging trials suggest that increasing HDL in clinical patients will decrease the risk of cardiovascular disease. Proposed mechanisms by which HDL may reduce atherosclerosis include facilitating cholesterol efflux from cholesterol-loaded foam cells, role as an antiinflammatory lipoprotein, decreasing atherogenic oxidized low-density lipoprotein, increasing nitric oxide synthesis, serving as a plasma transport lipoprotein for biologically important proteins, and as an antithrombotic agent. The identification of the major receptors, enzymes, cellular transporters, and plasma lipid transfer proteins has provided major new insights into the pathways for HDL metabolism and cholesterol transport as well as targets for future drug development to increase HDL. Conclusions: Clinical trials with new HDL-raising drugs are currently under way to provide definitive evidence that increasing HDL will reduce cardiovascular events. The marked increase in our knowledge of the roles of HDL in cholesterol transport and the development of atherosclerosis now provides the framework for a more effective assessment of the plasma level and the function of HDL in an individual patient, as well as the lipoprotein profile after new drugs that increase HDL. Copyright © 2011 by The Endocrine Society.
Shara N.M.,MedStar Research Institute
Nutrition, Metabolism and Cardiovascular Diseases | Year: 2010
Morbidity and mortality from cardiovascular disease (CVD) are rising among Middle Eastern women. Despite this threat, awareness and understanding of CVD are low and surveillance data are nonexistent for many populations in this region. In this review, the data available on CVD in Middle Eastern women will be generalized. Population-based studies in the Middle East have been sporadic and most have been cross-sectional with small samples. Many Middle Eastern countries lack reliable surveillance data regarding the prevalence and incidence of CVD and its risk factors in women. This information is crucial for monitoring the scope of the problem and for guiding intervention strategies. Because of the ethnic heterogeneity of this region and the rapidly changing lifestyles, well-designed, longitudinal, large-scale population-based studies that focus on CVD and its risk factors are needed in multiple areas of the Middle East. © 2010 Elsevier B.V.
MedStar Research Institute | Date: 2011-04-05
Described herein are conditioned medium and processed conditioned medium, each of which comprises secreted stem cell factors; compositions containing conditioned medium and/or processed conditioned medium and a delivery polymer. The conditioned medium, processed conditioned medium and compositions may be used to promote blood vessel growth and healing of injured tissues.
Genway Biotech Inc., Emory University and MedStar Research Institute | Date: 2012-03-01
This invention relates to the area of cardiovascular disorders and specifically relates to methods of diagnostic tests using a combination of markers to predict an individuals risk for developing coronary artery disease (CAD) and related diseases, such as angina pectoris and peripheral vascular disease and, more particularly, to determine an individuals risk of myocardial infarction, death, and stroke. Exemplary biomarkers include C-reactive protein (CRP), fibrin degradation products (FDPs), Heat Shock Protein 70 (HSP70), and/or anti-CMV antibody.
MedStar Research Institute and Georgetown University | Date: 2013-04-15
Described herein are polypeptides that home to developing microvasculature, (also referred to as developing microvessels), such as newly developing microvasculature in mammals, particularly in humans, and to DNA that encodes such polypeptides. These polypeptides are referred to herein as developing microvasculature homing polypeptides. In a specific embodiment, the homing peptides are collateral vessel endothelia (CVE) homing polypeptides, which have been shown to home to collateral vessel endothelia after ischemia.
MedStar Research Institute and Georgetown University | Date: 2010-10-09
Described herein are homing polypeptides that home to atherosclerotic plaque(s) in mammals and nucleic acids that encode such polypeptides. Also described are methods for detecting and treating conditions or disorders associated with, or characterized, by elevated levels of homing polypeptides that home to atherosclerotic plaque and/or vulnerable plaque.
MedStar Research Institute | Date: 2013-09-06
A non-invasive system, and method for simple, quantitative screening for mTBI and other forms of mid cognitive impairment using a visuo-motor performance test (for example, a submaximal grip test) in response to visual feedback to quantitatively measure the intra-individual variability of performance metric for initial screening of patients with mild traumatic brain injury (mTBI), and other neurological disorders. The system and method can be administered in minutes, by any level of caregiver, in any environment including military in-the-field or sports on-field deployments, and is useful in screening those truly injured from those disguising or mimicking injury. In addition to screening, the system and method can be used to monitor and/or detect changes to intra-individual variability over time by comparison to a baseline, which in turn is helpful in determining estimated recovery trajectory or other related information.
News Article | November 16, 2016
WASHINGTON, DC--(Marketwired - November 16, 2016) - Suzanne Groah, MD, MSPH, has been awarded a $500,000 grant by the Craig H. Neilsen Foundation to support screening for urinary tract infections (UTIs) among patients with spinal cord injuries at MedStar National Rehabilitation Network. "Urinary tract infection is the most common bacterial infection seen in the outpatient setting and the most common healthcare-associated infection, making it a major worldwide public health problem," said Dr. Groah. In addition, spinal cord injury patients are at high risk for recurrent UTI, which is known to cause significant pain and discomfort; however, mobility limitations often create barriers to these patients receiving comprehensive care. The study, "Development of a Urinary Symptom Questionnaire for People with Neuropathic Bladder," will develop a questionnaire for individuals being treated for bladder dysfunction due to spinal cord injury to assist them in self-assessments of their health. The process of creating the questionnaire is centered on working with patients with spinal cord injuries, focusing on utilizing their feedback to develop usable tools for others through focus groups and interviews. Focus groups will help develop the questionnaire, which will be validated and assessed by a large, diverse, national sample of people living with spinal cord injury. The goal is that other patients will be able to use the tool to self-assess if their symptoms may be related to a UTI. "When the study team surveyed people with neuropathic bladder due to spinal cord injury and spina bifida, we found that UTI is a problem for more than 80 percent of people," Dr. Groah said. By creating this tool, Dr. Groah's research team will have an enhanced diagnostic approach to UTIs within this population that will be useful in future research, clinical care, patient education, and patient and clinical decision-making. This research is building on a study that currently is recruiting patients, "The Impact of Self-Management with Probiotics on Urinary Symptoms and the Urine Microbiome in Individuals with Spinal Cord Injury and Spina Bifida," which was funded by a Patient-Centered Outcomes Research Institute grant in 2014. Dr. Groah is the director of Spinal Cord Injury Consultation Liaison Service and of Spinal Cord Injury Research at MedStar National Rehabilitation Network and associate professor of rehabilitation medicine at Georgetown University. The Craig H. Neilsen Foundation's funding is dedicated to supporting both programs and scientific research to improve the quality of life for those affected by and living with spinal cord injury. The MedStar Health Research Institute is the research arm of MedStar Health, the largest healthcare provider in Maryland and the Washington, D.C., region. MHRI provides scientific, administrative and regulatory support for research programs throughout the MedStar Health system. MHRI's expertise includes translational research into disease prevention, diagnosis and treatment. These programs complement the key clinical services and teaching programs in the 10 MedStar hospitals and other MedStar entities. For more information, visit MedStarResearch.org. MedStar Health is a not-for-profit health system dedicated to caring for people in Maryland and the Washington, D.C., region, while advancing the practice of medicine through education, innovation and research. MedStar's 30,000 associates, 6,000 affiliated physicians, 10 hospitals, ambulatory care and urgent care centers, and the MedStar Health Research Institute are recognized regionally and nationally for excellence in medical care. As the medical education and clinical partner of Georgetown University, MedStar trains more than 1,100 medical residents annually. MedStar Health's patient-first philosophy combines care, compassion and clinical excellence with an emphasis on customer service. For more information, visit MedStarHealth.org
News Article | December 20, 2016
HYATTSVILLE, MD--(Marketwired - December 20, 2016) - MedStar Health Research Institute was awarded grant funding for three research initiatives through the Charles and Mary Latham Fund, established by Ella O. Latham, to support medical research in the Washington, D.C., metropolitan area. The three MedStar Health research projects that were awarded funding are: "Our researchers are committed to pursuing clinical research that advances the health of our local Washington, D.C. metro community," said Neil J. Weissman, MD, president of MedStar Health Research Institute. "We are extremely appreciative for the support we have received from the Charles and Mary Latham Fund and its corporate trustee, SunTrust, to continue our commitment to better outcomes for our patients." The Charles and Mary Latham Fund was established by Ella O. Latham in memory of her parents. Founded in 1972, the Fund has supported a myriad of worthwhile projects relating to medical research for the cure of diseases in the human body with a preference for clinical applications and medical, nursing, and hospital care for persons suffering from such diseases who are financially unable to provide their own care. About MedStar Health Research Institute The MedStar Health Research Institute is the research arm of MedStar Health, the largest healthcare provider in Maryland and the Washington, D.C., region. MHRI provides scientific, administrative and regulatory support for research programs throughout the MedStar Health system. MHRI's expertise includes translational research into disease prevention, diagnosis and treatment. These programs complement the key clinical services and teaching programs in the 10 MedStar hospitals and other MedStar entities. For more information, visit www.MedStarResearch.org. About MedStar Health MedStar Health is a not-for-profit health system dedicated to caring for people in Maryland and the Washington, D.C., region, while advancing the practice of medicine through education, innovation and research. MedStar's 31,000 associates, 6,500 affiliated physicians, 10 hospitals, ambulatory care and urgent care centers, and the MedStar Health Research Institute are recognized regionally and nationally for excellence in medical care. As the medical education and clinical partner of Georgetown University, MedStar trains more than 1,100 medical residents annually. MedStar Health's patient-first philosophy combines care, compassion and clinical excellence with an emphasis on customer service. For more information, visit www.MedStarHealth.org.